The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
Open accessAbstract
Cannabinoids act at two classical cannabinoid receptors (CB 1 and CB 2), a 7TM orphan receptor and the transmitter‐gated channel transient receptor potential vanilloid type‐1 receptor. Recent evidence also points to cannabinoids acting at members of the nuclear receptor family, peroxisome proliferator‐activated receptors (PPARs, with three subtypes α, β (δ) and γ), which regulate cell differentiation and lipid metabolism. Much evidence now suggests that endocannabinoids are natural activators of PPAR α. Oleoylethanolamide regulates feeding and body weight, stimulates fat utilization and has neuroprotective effects mediated through activation of PPAR α. Similarly, palmitoylethanolamide regulates feeding and lipid metabolism and has anti‐inflammatory properties mediated by PPAR α. Other endocannabinoids that activate PPAR α include anandamide, virodhamine and noladin. Some (but not all) endocannabinoids also activate PPAR γ; anandamide and 2‐arachidonoylglycerol have anti‐inflammatory properties mediated by PPAR γ. Similarly, ajulemic acid, a structural analogue of a metabolite of Δ 9‐tetrahydrocannabinol (THC), causes anti‐inflammatory effects in vivo through PPAR γ. THC also activates PPAR γ, leading to a time‐dependent vasorelaxation in isolated arteries. Other cannabinoids which activate PPAR γ include N‐arachidonoyl‐dopamine, HU210, WIN55212‐2 and CP55940. In contrast, little research has been carried out on the effects of cannabinoids at PPARδ. In this newly emerging area, a number of research questions remain unanswered; for example, why do cannabinoids activate some isoforms and not others? How much of the chronic effects of cannabinoids are through activation of nuclear receptors? And importantly, do cannabinoids confer the same neuro‐ and cardioprotective benefits as other PPAR α and PPAR γ agonists? This review will summarize the published literature implicating cannabinoid‐mediated PPAR effects and discuss the implications thereof. British Journal of Pharmacology (2007) 152, 576–582; doi:10.1038/sj.bjp.0707423; published online 20 August 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · cited 3×
“The eicosanoids 15- deoxy-D-l2,14-prostaglandin J2 and 8(S)-hydroxyeicosatetraenoic acid (8(S)-HETE) interact with PPARs with an EC50 of approximately 500 nM (Kliewer et al., 1997).”
BackgroundFu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodríguez de Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., et al. (2003) · Nature · doi:10.1038/nature01921 · Cited by 1,064
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
The Biology of Peroxisome Proliferator-Activated Receptors
Ferré, P. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s43 · Cited by 776
Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 697
Matias, I., Gonthier, M.-P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2679 · Cited by 656
PPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641 · cited 3×
“…hyperli- pidemia, atherosclerosis, metabolic syndrome and neuro- degenerative disorders (for reviews see Francis et al., 2003; Fenner and Elstner, 2005; Barish et al., 2006; Glass, 2006; Leo et al., 2007; Stienstra et al., 2007), cannabinoid actions at PPARs would provide an alternative mechanism…”
BackgroundMoreno, S., Farioli-Vecchioli, S., & Cerù, M. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.064 · Cited by 587
Peroxisome proliferator-activated receptor γ in diabetes and metabolism
Rangwala, S. M., & Lazar, M. A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.012 · Cited by 450
Demuth, D. G., & Molleman, A. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.055 · Cited by 420
Cited by
An Introduction to the Endogenous Cannabinoid System
Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
An update on PPAR activation by cannabinoids
O'Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 449
Self-citationCannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
The Endocannabinoid System and its Modulation by Phytocannabinoids
Di Marzo, V., & Piscitelli, F. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0374-6 · Cited by 432
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410
“The recently discovered ability of different cannabinoids, including CBD, to display an extra-cannabinoid receptor binding activity has been highlighted by the observation that these compounds may go nuclear to exert their activity through the interaction with peroxisome proliferator-activated receptors (PPARs) [10].”
BackgroundThreatened by mining, polymetallic nodules are required to preserve abyssal epifauna
Vanreusel, A., Hilario, A., Ribeiro, P. A., Menot, L., & Arbizu, P. M. (2016) · Scientific Reports · doi:10.1038/srep26808 · Cited by 302
Cannabinoids and Cytochrome P450 Interactions
Zendulka, O., Dovrtělová, G., Nosková, K., Turjap, M., Šulcová, A., Hanuš, L., & Juřica, J. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151210142051 · Cited by 291
Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease
Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.-P., Teng, Z., & Chen, C. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.030 · Cited by 271
The cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 267
Diversity of molecular targets and signaling pathways for CBD
de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 257
Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Finn, D. P., Haroutounian, S., Hohmann, A. G., Krane, E., Soliman, N., & Rice, A. S. C. (2021) · Pain · doi:10.1097/j.pain.0000000000002268 · Cited by 254
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
“CBD acts like a PPARγ agonist through receptor-dependent mechanisms [23,234,235].”
BackgroundTargeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators
Pirat, C., Farce, A., Lebègue, N., Renault, N., Furman, C., Millet, R., Yous, S., Speca, S., Berthelot, P., Desreumaux, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm101360s · Cited by 198
Phytocannabinoids beyond the Cannabis plant – do they exist?
Gertsch, J., Pertwee, R. G., & Di Marzo, V. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00745.x · Cited by 188
Moreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177
Therapeutic potential of cannabis-related drugs
Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149
Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0304-z · Cited by 143
Dobrosi, N., Tóth, B. I., Nagy, G., Dózsa, A., Géczy, T., Nagy, L., Zouboulis, C. C., Paus, R., Kovács, L., & Bíró, T. (2008) · The FASEB Journal · doi:10.1096/fj.07-104877 · Cited by 142
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Iannotti, F. A., & Vitale, R. M. (2021) · Cells · doi:10.3390/cells10030586 · Cited by 130
Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation
Hermanson, D. J., Hartley, N. D., Gamble-George, J., Brown, N., Shonesy, B. C., Kingsley, P. J., Colbran, R. J., Reese, J., Marnett, L. J., & Patel, S. (2013) · Nature Neuroscience · doi:10.1038/nn.3480 · Cited by 126
“However, both approaches increase non-eCB lipids (NAEs for FAAH inhibition and MAGs for MAGL inhibition) that have biological actions at targets other than cannabinoid receptors 42 .”
Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., Guaza, C., Di Marzo, V., & Docagne, F. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06377.x · Cited by 109
“two extracellular cannabinoid receptors, termed CB1 and CB2, and several other, still not identified receptors (Brown, 2007), which could include members of the peroxisome proliferator-activated receptor (PPAR) family of intracellular receptors and of the transient receptor potential (TRP) family of channels (De Petro…”
BackgroundCannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis
Fukuda, S., Kohsaka, H., Takayasu, A., Yokoyama, W., Miyabe, C., Miyabe, Y., Harigai, M., Miyasaka, N., & Nanki, T. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-275 · Cited by 93
Endocannabinoids and pregnancy.
Taylor, A. H., Amoako, A. A., Bambang, K., Karasu, T., Gebeh, A., Lam, P. M. W., Marzcylo, T. H., & Konje, J. C. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.03.012 · Cited by 89
Barichello, T., Ceretta, R. A., Generoso, J. S., Moreira, A. P., Simões, L. R., Comim, C. M., Quevedo, J., Vilela, M. C., Zuardi, A. W., Crippa, J. A., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.053 · Cited by 76
Karbarz, M. J., Luo, L., Chang, L., Tham, C.-S., Palmer, J. A., Wilson, S. J., Wennerholm, M. L., Brown, S. M., Scott, B. P., Apodaca, R. L., et al. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31818c7cbd · Cited by 74
“The FAA metabolizing enzymes currently identified include two isoforms of fatty acid amide hydrolase (FAAH11), and N-acylethanolaminehydrolyzing acid amidase,12 which preferentially hydrolyzes PEA.”
BackgroundDunn, S. L., Wilkinson, J. M., Crawford, A., Le Maitre, C. L., & Bunning, R. A. D. (2014) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2013.10.016 · Cited by 46
Metadata
- Authors
- O'Sullivan, S. E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 576-582
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2120367130
- Cited by
- 510
- References
- 43
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.